X4 Pharmaceuticals secured a $150M senior secured term loan facility with K2 HealthVentures to repay existing debt and fund corporate activities. This deal strengthens financial flexibility ahead of anticipated FDA approval for mavorixafor.
X4 Pharmaceuticals secured a $150M senior secured term loan facility with K2 HealthVentures to repay existing debt and fund corporate activities. This deal strengthens financial flexibility ahead of anticipated FDA approval for mavorixafor.